Table 2.
Patients | Age | Gender | Cirrhosis | HBsAg | HBcAb | AFP | CA19-9 | Tumor size | LNM | VI | APE |
---|---|---|---|---|---|---|---|---|---|---|---|
Patient 1 | 56 | Male | Present | Positive | Positive | 5.09 | 14.21 | 2.5 cm | Negative | Negative | Positive |
Patient 2 | 45 | Male | Absent | Positive | Positive | 1 | 143.8 | 11 cm | Negative | Negative | Positive |
Patient 3 | 54 | Female | Absent | Positive | Positive | 3.8 | 13.8 | 3 cm | Negative | Negative | Positive |
Patient 4 | 62 | Female | Present | Positive | Positive | 1.7 | 33.4 | 9 cm | Negative | Negative | Positive |
Patient 5 | 46 | Male | Present | Positive | Positive | 2175 | 1998 | 14 cm | Positive | Positive | Positive |
Patient 6 | 48 | Female | Present | Positive | Positive | 125 | 35 | 3.5 cm | Negative | Negative | Positive |
Patient 7 | 61 | Male | Present | Positive | Positive | 309.4 | 54.8 | 12 cm | Positive | Negative | Positive |
Patient 8 | 68 | Male | Present | Positive | Positive | 9.7 | 53.3 | 16 cm | Negative | Positive | Positive |
Patient 9 | 61 | Male | Present | Positive | Positive | 1.6 | 15.1 | 6 cm | Negative | Positive | Positive |
TACE: transarterial chemoembolization, HBsAg: hepatitis B surface antigen, HBcAb: hepatitis B core antibody, AFP: alpha fetoprotein, CA19-9: carbohydrate antigen 19-9, LNM: lymph node metastasis, VI: vascular invasion, APE: arterial phase enhancement